Navigation Links
Palatin Technologies Announces Third Quarter Fiscal Year 2013 Results and Update on Development of Bremelanotide for Female Sexual Dysfunction
Date:5/14/2013

cessful NDA filing and furthering our discussions with potential collaboration partners."

Based upon the discussions with FDA, Palatin intends to finalize the protocols for the pivotal Phase 3 clinical studies and start screening patients later this year.

Quarter Ended March 31, 2013 Financial Results
For the three months ended March 31, 2013, Palatin reported a net loss of $4.0 million, or $(0.04) per basic and diluted share, compared to a net loss of $6.0 million, or $(0.17) per basic and diluted share, for the same period in 2012. 

The decrease in net loss for the quarter ended March 31, 2013, compared to the same period last fiscal year, is attributable to a decrease in operating expenses primarily related to Palatin's Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for the treatment of FSD. 

Revenue
Palatin did not recognize any revenues for the quarter ended March 31, 2013, compared to $23,996 for the quarter ended March 31, 2012.  Revenue consists of contract revenue under our collaboration agreement with AstraZeneca.

Costs and Expenses
Total operating expenses for the quarter ended March 31, 2013 were $4.0 million compared to $6.1 million for the comparable quarter of 2012.  The decrease in operating expenses for the quarter was primarily due to Palatin's Phase 2B clinical trial with bremelanotide for FSD and secondarily as a result of closing our research laboratory operations in connection with the lease expiration of the laboratory facilities in July 2012.

Cash Position
As of March 31, 2013, Palatin had cash and cash equivalents of $23.5 million, $6.0 million in short term investments and current liabilities of $2.7 million.  Cash and cash equivalents as of June 30, 2012 were $3.8 million with current liabilities of $3.5 million. 

Palatin believes that its existing capital resources will be adequate to fund its currently planned opera
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Palatin Technologies, Inc. To Report Fiscal Year 2013 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2013
2. Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-Specific Peptides for Sexual Dysfunction
3. Palatin Technologies To Present At The 25th Annual ROTH Conference
4. Palatin Technologies, Inc. To Present At The Cowen & Company 33rd Annual Health Care Conference
5. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on February 14, 2013
6. Palatin Technologies, Inc. To Report Fiscal Year 2013 Second Quarter Results; Teleconference and Webcast to be held on February 14, 2013
7. Palatin Technologies, Inc. to Present at 15th Annual BIO CEO & Investor Conference
8. Palatin Technologies, Inc. to Present at the 24th Annual Piper Jaffray Healthcare Conference
9. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on November 14, 2012
10. Palatin Technologies, Inc. To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
11. Palatin Technologies, Inc. To Report Fiscal Year 2013 First Quarter Results; Teleconference and Webcast to be held on November 14, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... ... August 04, 2015 , ... RPS Diagnostics ... – today announced that Robert A. Gregg, PhD, has joined RPS as Senior ... years of relevant experience and remarkable achievements in the medical device and diagnostics ...
(Date:8/4/2015)... ... August 04, 2015 , ... On August 4, 2015, ... diverse selection of entrepreneurs from across the United States to talk about their experiences ... honored to be chosen to be among the attendees. , One of the day’s ...
(Date:8/3/2015)... , Aug. 3, 2015  ArroGen Group, an ... new Fingerprint Molecular Identification™ (FMID) technology Aug. 2-8 ... in Sacramento, Calif. ... will enable law enforcement agents, district attorneys and ... criminal suspects. By analyzing chemical residues ...
(Date:8/3/2015)... , Aug. 3, 2015  Merck KGaA, Darmstadt, ... innovative and top-quality high-tech products in the healthcare, life ... the US-based company Nano-C, their development and launch of ... organic photovoltaics (OPV). Merck KGaA, Darmstadt, Germany ... the growing OPV sector. Novel derivatives: highly ...
Breaking Biology Technology:RPS Diagnostics Welcomes Robert Gregg as Senior Vice President of Clinical and Regulatory Affairs 2RPS Diagnostics Welcomes Robert Gregg as Senior Vice President of Clinical and Regulatory Affairs 3White House Invites uBiome CEO Jessica Richman to First-Ever Startup Demo Day 2ArroGen Previews New Fingerprint Molecular Identification Technology 2Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 2Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 3Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 4
... and RESEARCH TRIANGLE PARK, N.C., June 8 CSL Limited ... have mutually agreed to terminate their merger agreement, announced on ... for US$3.1 billion in cash. , , Dr. Brian ... are disappointed that the U.S. Federal Trade Commission (FTC) resolved ...
... , , INCLINE VILLAGE, Nev., June 8 ... announced revenue guidance for the second quarter ended June 30, ... for the second quarter of 2008. The increase is due ... Avastin(R), and Lucentis(R), which are marketed by Genentech, and sales ...
... a west coast session of NCCN Academy for Excellence ... Business scheduled for July 9 - 10, 2009 in ... give pharmaceutical and biotech professionals the rare opportunity to ... operational issues from the provider and payer perspective. , ...
Cached Biology Technology:CSL Limited and Talecris Biotherapeutics Agree to Terminate Merger Agreement 2CSL Limited and Talecris Biotherapeutics Agree to Terminate Merger Agreement 3PDL BioPharma Provides Second Quarter 2009 Revenue Guidance of Approximately $125 Million 2PDL BioPharma Provides Second Quarter 2009 Revenue Guidance of Approximately $125 Million 3Industry Professionals Get Schooled in Real-World Oncology Issues at NCCN Academy 2Industry Professionals Get Schooled in Real-World Oncology Issues at NCCN Academy 3Industry Professionals Get Schooled in Real-World Oncology Issues at NCCN Academy 4
(Date:7/9/2015)... DUBLIN , July 07, 2015 ... has announced the addition of the "Biometrics ... and Forecasts 2015-2020" report to their offering. ... a major contributor to this growth and the ... US$5.5 billion in revenue for companies involved in ...
(Date:7/9/2015)... JOSE, Calif. , July 9, 2015 ... the leading developer of human interface solutions, ... technology, the industry,s first fully hardware encapsulated ... Match-in-Sensor secure authentication technology is literally off ... storage and biometric matching within the fingerprint ...
(Date:7/8/2015)... FRANKLIN LAKES , N.J. and NEW YORK ... and Company) and Guidepoint today announced ... selected start-up healthcare companies with free access to Guidepoint,s ... mentoring several start-ups that are developing cutting-edge technologies to ... of a dedicated Guidepoint research manager, each start-up entrepreneur ...
Breaking Biology News(10 mins):Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3
... study shows that the exposure to the controversial chemical Bisphenol ... tests. In the study, researchers compared BPA concentrations in mice ... the day, compared to the more common lab method of ... BPA in the blood of mice. This is the ...
... knows that newborns still have a lot of neurological work ... variety of nascent animals, genes provide them with only a ... nervous system to do its own finish work. Two studies ... for exposure to light in the environment as mouse pups ...
... New York June 5, 2011 Moisture and ... form a critical nexus between surface hydrology and atmospheric ... has suggested that soil moisture has had a positive ... observations of this. A team of researchers from Columbia ...
Cached Biology News:Exposure to BPA has been underestimated, new MU research says 2Early light refines the brain's circuitry for vision 2Early light refines the brain's circuitry for vision 3Early light refines the brain's circuitry for vision 4Columbia Engineering team makes major step in improving forecasts of weather extremes 2
Fast, sensitive quantitation of total MEK 1/2 concentration....
Argon Calibration Source...
RayBio Human Chemokine Antibody Array 1.1 (8) with Accessory, detects 38 chemokine factors (for lysate) Class: Antibody Array Products Product Group: Antibody Array...
Vybrant® Multidrug Resistance Assay Kit...
Biology Products: